Molecular effects of L-dopa therapy in Parkinson's disease

Current Genomics

Volumn 15, Issue 1, 2014, Pages 11-17

  Dorszewska, Jolanta ^a   Prendecki, Michal ^a   Lianeri, Margarita ^a   Kozubski, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biothiols; Immune response; L dopa; Oxidative stress; PD

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TUBULIN; BETA TUBULIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; LEVODOPA; NEUROTRANSMITTER; PYRIDOXINE;

APOPTOSIS; ARTICLE; DISEASE COURSE; DISEASE TRANSMISSION; HOEHN AND YAHR SCALE; HUMAN; IMMUNE RESPONSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; QUALITY OF LIFE; RESPIRATORY CHAIN;

EID: 84896320898     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202914666131210213042     Document Type: Article

References (68)

1. Hughes, A.J.; Daniel, S.E.; Ben-Shlomo, Y.; Lees, A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 2002, 125(4), 861-870.
2. Hussl, A.; Seppi, K.; Poewe, W. Nonmotor symptoms in Parkinson's disease. Expert Rev. Neurother., 2013, 13(6), 581-583.
3. Hermanowicz, N. Drug therapy for Parkinson's disease. Semin. Neurol., 2007, 27(2), 97-105.
4. Ehringer, H.; Hornykiewicz, O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr., 1960, 38, 1236-1239.
5. Sulzer, D.; Zecca, L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res., 2000, 1(3), 181-195.
6. Gesi, M.; Santinami, A.; Ruffoli, R.; Conti, G.; Fornai, F. Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). Pharmacol. Toxicol., 2001, 89(5), 217-224.
7. Khan, F.H.; Saha, M.; Chakrabarti, S. Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain Res., 2001, 895(1-2), 245-249.
8. Andican, G.; Konukoglu, D.; Bozluolcay, M.; Bayülkem, K.; Firtii{dotless}na, S.; Burcak, G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol. Belg., 2012, 112(2), 155-159.
9. Dorszewska, J.; Kozubski, W. Oxidative DNA damage and the level of biothiols, and L-dopa therapy in Parkinson's Disease. In: Etiology and Pathophysiology of Parkinson's Disease, ed.; Rana A.Q.; Eds.; In Tech, 2011; pp. 349-372.
10. Berman, S.B.; Hastings, T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem., 1999, 73(3), 1127-1137.
11. Kuhn, D.M.; Arthur, R.E.; Thomas, D.M.; Elferink, L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem., 1999, 73(3), 1309-1317.
12. Lynch-Day, M.A.; Mao, K.; Wang, K.; Zhao, M.; Klionsky, D.J. The role of autophagy in Parkinson's disease. Cold Spring Harb. Perspect Med., 2012, 2(4), a009357.
13. Munoz, P.; Huenchuguala, S.; Paris, I.; Segura-Aguilar, J. Dopamine oxidation and autophagy. Parkinsons Dis., 2012, 920953. doi: 10.1155/2012/920953.
14. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38(8), 1285-1291.
15. Rowe, D.B.; Le, W.; Smith, R.G.; Appel, S.H. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J. Neurosci. Res., 1998, 53(5),551-558.
16. Yamada, T.; McGeer, P.L.; McGeer, E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol., 1992, 84(1), 100-104.
17. Duan, W.; Ladenheim, B.; Cutler, R.G.; Kruman, I.I.; Cadet, J.L.; Mattson, M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem., 2002, 80(1), 101-110.
18. Kuhn, W.; Roebroek, R.; Blom, H.; van Oppenraaij, D.; Przuntek, H.; Kretschmer, A.; Büttner, T.; Woitalla, D.; Müller, T. Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol., 1998, 40(4), 225-227.
19. Hornykiewicz, O.; Kish, S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol., 1987, 45, 19-34.
20. Martinez, M.; Brice, A.; Vaughan, J.R.; Zimprich, A.; Breteler, M.M.; Meco, G.; Filla, A.; Farrer, M.J.; Bétard, C.; Hardy, J.; De Michele, G.; Bonifati, V.; Oostra, B.; Gasser, T.; Wood, N.W.; Dürr, A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. J. Med. Genet., 2004, 41(12), 900-907.
21. Deumens, R.; Blokland, A.; Prickaerts, J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol., 2002, 175(2), 303-317.
22. Armañanzas, R., Bielza, C.; Chaudhuri, K.R.; Martinez-Martin, P.; Larrañaga, P. Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach. Artif. Intell. Med., 2013, 58(3), 195-202.
23. Wright, B.A.; Waters, C.H. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert Rev. Neurother., 2013, 13(6), 719-729.
24. Lovenberg, W.; Weissbach, H.; Udenfriend, S. Aromatic L-amino acid decarboxylase. J. Biol. Chem., 1962, 237, 89-93.
25. Kostrzewa, R.M.; Nowak, P.; Kostrzewa, J.P.; Kostrzewa, R.A.; Brus, R. Peculiarities of L:-DOPA treatment of Parkinson's disease. Amino Acids., 2005, 28(2), 157-164.
26. Pattison, D.I.; Dean, R.T.; Davies, M.J. Oxidation of DNA, proteins and lipids by DOPA, protein-bound DOPA, and related catechol(amine)s. Toxicology., 2002, 177(1), 23-37.
27. Sherer, T.B.; Betarbet, R.; Greenamyre, J.T. Environment, mitochondria, and Parkinson's disease. Neuroscientist., 2002, 8(3), 192-197.
28. Gluck, M.; Ehrhart, J.; Jayatilleke, E.; Zeevalk, G.D. Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J. Neurochem., 2002, 82(1), 66-74.
29. Reale, M.; Pesce, M.; Priyadarshini, M.; Kamal, M.A.; Patruno, A. Mitochondria as an easy target to oxidative stress events in Parkinson's disease. CNS Neurol. Disord. Drug Targets., 2012, 11(4), 430-438.
30. Subramaniam, S.R.; Chesselet, M.F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol., 2013, 106, 17-32.
31. Floor, E.; Wetzel, M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem., 1998, 70(1), 268-275.
32. Kikuchi, A.; Takeda, A.; Onodera, H.; Kimpara, T.; Hisanaga, K.; Sato, N.; Nunomura, A.; Castellani, R.J.; Perry, G.; Smith, M.A.; Itoyama, Y. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis., 2002, 9(2), 244-248.
33. Hirano, T. Repair system of 7, 8-dihydro-8-oxoguanine as a defense line against carcinogenesis. J. Radiat. Res., 2008, 49(4), 329-340.
34. Spencer, J.P.; Jenner, P.; Halliwell, B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport, 1995, 6(11), 1480-1484.
35. Dorszewska, J.; Florczak, J.; Rozycka, A.; Jaroszewska-Kolecka, J.; Trzeciak, W.H.; Kozubski, W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell. Biol., 2005, 24(12), 786-794.
36. Dorszewska, J.; Kempisty, B.; Jaroszewska-Kolecka, J.; Rozycka, A.; Florczak, J.; Lianeri, M.; Jagodziski, P.P.; Kozubski, W. Expression and polymorphisms of gene 8-oxoguanine glycosylase 1 and the level of oxidative DNA damage in peripheral blood lymphocytes of patients with Alzheimer's disease. DNA Cell. Biol., 2009, 28(11), 579-588.
37. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
38. Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol., 2000, 157(2), 401-410.
39. Zhou, J.X.; Zhang, H.B.; Huang, Y.; He, Y.; Zheng, Y.; Anderson, J.P.; Gai, W.P.; Liang, Z.G.; Wang, Y., Ren, X.M.; Wang, Q.; Gong, X.L.; Yang, J.; Wang, X.; Halliday, G.; Wang, X.M. Tenuigenin Attenuates α-Synuclein-Induced Cytotoxicity by Down-Regulating Polo-Like Kinase 3. CNS Neurosci. Ther., 2013, 19(9), 688-94.
40. Conway, K.A.; Rochet, J.C.; Bieganski, R.M.; Lansbury, P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 2001, 294(5545), 1346-1349.
41. Alves Da Costa, C.; Paitel, E.; Vincent, B.; Checler, F. Alphasynuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem., 2002, 277(52), 50980-50984.
42. Blandini, F.; Cosentino, M.; Mangiagalli, A.; Marino, F.; Samuele, A.; Rasini, E.; Fancellu, R.; Tassorelli, C.; Pacchetti, C.; Martignoni, E.; Riboldazzi, G.; Calandrella, D.; Lecchini, S.; Frigo, G.; Nappi, G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural. Transm., 2004, 111(8), 1017-1030.
43. Hirsch, E.C.; Hunot, S.; Faucheux, B.; Agid, Y.; Mizuno, Y.; Mochizuki, H.; Tatton, W.G.; Tatton, N.; Olanow, W.C. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord., 1999, 14(2), 383-385.
44. Matsui, Y.; Kyoi, S.; Takagi, H.; Hsu, C.P.; Hariharan, N.; Ago, T.; Vatner, S.F.; Sadoshima, J. Molecular mechanisms and physiological significance of autophagy during myocardial ischemia and reperfusion. Autophagy, 2008, 4(4), 409-415.
45. Clement MV, Long LH, Ramalingam J, Halliwell B. The cytotox icity of dopamine may be an artefact of cell culture. J. Neurochem., 2002, 81(3), 414-421.
46. Mytilineou, C.; Walker, R.H.; JnoBaptiste, R.; Olanow, C.W. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther., 2003, 304(2), 792-800.
47. Jia, Z.; Zhu, H.; Misra, B.R.; Li, Y.; Misra, H.P. Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection. Neurochem. Res., 2008, 33(11), 2197-2205.
48. Hunot, S.; Hirsch, E.C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol., 2003, 53 Suppl 3:S49-58.
49. Hald, A.; Lotharius, J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol., 2005, 193(2), 279-290.
50. Quadri, R.; Comino, I.; Scarzella, L.; Cacioli, P.; Zanone, M.M.; Pipieri, A.; Bergamasco, B.; Chiandussi, L. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration. Funct. Neurol., 2000, 15(2), 81-86.
51. Gorell, J.M.; Johnson, C.C.; Rybicki, B.A. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology, 1994, 44(10), 1865-1868.
52. Miller, J.W.; Selhub, J.; Nadeau, M.R.; Thomas, C.A.; Feldman, R.G.; Wolf, P.A. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2003, 60(7), 1125-1129.
53. O'Suilleabhain, P.E.; Bottiglieri, T.; Dewey, R.B.; Sharma, S.; Diaz-Arrastia, R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov. Disord., 2004, 19(12), 1403-1408.
54. Miller, J.W.; Shukitt-Hale, B.; Villalobos-Molina, R.; Nadeau, M.R.; Selhub, J.; Joseph, J.A. Effect of L-Dopa and the catechol-Omethyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol., 1997, 20(1), 55-66.
55. Yasui, K.; Nakaso, K.; Kowa, H.; Takeshima, T.; Nakashima, K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol. Scand., 2003, 108(1), 66-67.
56. Müller, T.; Werne, B.; Fowler, B.; Kuhn, W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet, 1999, 354(9173), 126-127.
57. Dorszewska, J.; Florczak, J.; Rozycka, A.; Kempisty, B.; Jaroszewska-Kolecka, J.; Chojnacka, K.; Trzeciak, W.H.; Kozubski, W. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol. Exp. (Wars)., 2007, 67(2), 113-129.
58. Borowczyk, K.; Tisończyk, J.; Jakubowski, H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: protective role of bleomycin hydrolase. Amino Acids, 2012, 43(3), 1339-1348.
59. Ballatori, N. Glutathione mercaptides as transport forms of metals. Adv. Pharmacol., 1994, 27, 271-298.
60. Shen, X.M.; Xia, B.; Wrona, M.Z.; Dryhurst, G. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of Nacetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol., 1996, 9(7), 1117-1126.
61. Allen, G.F.; Ullah, Y.; Hargreaves, I.P.; Land, J.M.; Heales, S.J. Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states. Neurochem. Int., 2013, 62(5), 684-694.
62. Makar, T.K.; Nedergaard, M.; Preuss, A.; Gelbard, A.S.; Perumal, A.S.; Cooper, A.J. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem., 1994, 62(1), 45-53.
63. Griffith, O.W.; Meister, A. Glutathione: interorgan translocation, turnover, and metabolism. Proc. Natl. Acad. Sci. U S A, 1979, 76(11), 5606-5610.
64. Gegg, M.E.; Clark, J.B.; Heales, S.J. Co-culture of neurones with glutathione deficient astrocytes leads to increased neuronal susceptibility to nitric oxide and increased glutamate-cysteine ligase activity. Brain Res., 2005, 1036(1-2), 1-6.
65. Martínez-Banaclocha, M.A.; N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? Med. Hypotheses., 2012, 79(1), 8-12.
66. Hinz, M., Stein, A.; Uncini, T. Amino acid management of Parkinson's disease: a case study. Int. J. Gen. Med. 2011, 4, 165-174.
67. Müller, T. Possible treatment concepts for the levodopa-related hyperhomocysteinemia. Cardiovasc. Psychiatry Neurol., 2009, 9, 1-5.
68. Nevrly, M.; Kanovsky, P.; Vranova, H.; Langova, K.; Hlustik, P. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. Neurol. Sci., 2010, 31(5), 565-569.